Corixa, Ribi ImmunoChem deal

CRXA completed its acquisition of RIBI for $58.5 million, consisting of $48 million worth of CRXA stock in exchange for RIBI's 21 million shares outstanding, $7.9 million in cash for RIBI preferred shares, and $2.6 million in transaction costs (see BioCentury, June 14). CRXA has 14.8 million shares outstanding after the acquisition. ...